The Food and Drug Administration (FDA) is reporting a temporary shortage of Avycaz (ceftazidime and avibactam; Allergan) for Injection.

Avycaz for Injection is unavailable as of August 8, 2016 and the shortage is estimated to last 6 months. The reason for the shortage according to the FDA Safety and Innovation Act (FDASIA) of 2012 is due to a shortage of active ingredient. 

Avycaz for Injection was initially approved by the FDA in February 2015. It combines ceftazidime, a cephalosporin, and avibactam, a beta-lactamase inhibitor. It is indicated to treat susceptible infections including complicated intra-abdominal infections (cIAI), in combination with metronidazole, and complicated urinary tract infections (cUTI), including pyelonephritis. In the treatment of cUTI, as only limited clinical safety and efficacy data for Avycaz are currently available, the drug should be reserved for use in patients with cUTI who have limited or no alternative treatment option. 

Related Articles

The shortage affects both the single-use vial and the 10-count cartons. The interruption in supply is expected to resolve in the first quarter of 2017.

For more information visit